Abraham Bassan
Partner @ Samsara BioCapital
San Francisco Bay Area, United States
Abraham Bassan is a Series A investor at Samsara BioCapital in San Francisco Bay Area focused on Biotechnology and Medical. Abraham Bassan is based out of San Jose, California and is the Partner of Samsara BioCapital and Board of Directors at Rani Therapeutics. Abraham previously worked at Revolution Medicines as a Director of Program Biology. Abraham Bassan attended the Princeton University.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Abraham Bassan invests in
Stages Abraham Bassan invests in
Countries Abraham Bassan invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (67%)
- Medical 2 (33%)
- Health Care 1 (17%)
- Life Science 1 (17%)
- Therapeutics 1 (17%)
Stage
- Series A 4 (67%)
- Series B 2 (33%)
Country
- United States 3 (50%)
- United Kingdom 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug therapies for patients with kidney disease. The company’s primary work centers on advancing AP306, a therapeutic candidate designed to treat hyperphosphatemia—a condition of elevated phosphate levels that commonly affects individuals withchronic kidney disease on dialysis—by blocking key active phosphate transport pathways in the gut. In its operations, R1 Therapeutics works on progressing AP306 through mid- and late-stage clinical studies and aims to bring an alternative treatment option to patients struggling with phosphate management complications associated with chronic kidney disease. | $3M / Series A / Sep 30, 2026 | ||
| Link Cell Therapies develops engineered cell therapy technologies intended to create targeted CAR T-based treatments for cancer. The company applies proprietary logic-gating methods that require co-expression of multiple cancer antigens to activate therapeutic T cells, aiming to focus immune cell activity on tumor cells while reducing effects onnon-cancerous tissues. Its work spans programs for solid tumors and certain hematologic cancers, with lead candidates progressing through preclinical development and preparation for clinical research. Link Cell Therapies also explores additional platforms and therapeutic programs that build on its core targeting technology to expand applications of engineered cellular therapies. | $60M / Series A / Dec 15, 2025 | ||
| Septerna is a biotechnology company. | $150M / Series B / Jul 11, 2023 | ||
| Septerna is a biotechnology company. | $100M / Series A / Jan 27, 2022 | ||
| Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications totransform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations. | $150.7M / Series B / Mar 15, 2021 | ||
| Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications totransform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations. | $45M / Series A / Sep 16, 2020 |
Co-Investors
About Samsara BioCapital
Samsara Biocapital provides investment advisory services to help entrepreneurs turn their own ideas and visions into successful companies. Samsara BioCapital, as a results-driven organization, is always looking for ambitious and visionary partners with the drive and flexibility to take their company to the next level. Samsara BioCapital promotes biotech innovation and collaborates with inspiring companies as they develop important and innovative new therapies.
Samsara BioCapital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Abraham Bassan
Partner
|
|||
Michael Dybbs
Partner
|
|||
|
Christian Richard
Head of Public Research
|
|||
Marcos Milla
Venture Partner
|
|||
Srini Akkaraju
Founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Abraham Bassan invest in?
Abraham Bassan invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Abraham Bassan?
Public channels for Abraham Bassan include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Abraham Bassan last invest?
The most recent investment recorded for Abraham Bassan closed in Sep 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
